Biohaven Expands Patient Access to Migraine Treatment

Biohaven (New Haven, CT) has announced two updates regarding Nurtec® ODT (rimegepant), its FDA-approved medication to both treat and prevent migraine attacks in adults.

The company has secured additional commercial insurance coverage for Nurtec ODT starting in April 2022 that expands the total number of commercial lives covered to 96 percent, or approximately 255 million people via all channels.

FDA has also approved a label amendment of the Nurtec ODT Prescribing and Patient Information to include clinical lactation data in the Use in Specific Populations section as it relates to women who are breastfeeding. The label amendment was approved based on study data evaluating the excretion of a single dose of rimegepant 75 mg in the human milk of healthy lactating women, recently published in Breastfeeding Medicine.